Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial

Praxis Precision Medicines shares are trading higher Monday after it announced positive results from the EMBRAVE Part A Trial of Elsunersen. Importance Rank: 1 read more

Go to News Site